XBiotech: Q2 Earnings Snapshot
XBiotech | 10-Q: Q2 2024 Earnings Report
What's Going On With Small-Cap Cancer Focused XBiotech On Tuesday?
XBiotech Shares Are Trading Higher After the Company Shared Results From the 1-BETTER Study for Advanced Pancreatic Cancer.
XBiotech Says The Primary Endpoint For The Phase 2 Study Was To Assess The Safety And Tolerability Of Natrunix When Used With The ON+5FU+LV Combination, There Were Fewer Adverse Events Of Any Kind During The 24-Week Treatment Period For The Natrunix...
XBiotech Results From Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer